Author
Listed:
- Olga Koshkina
(University of Twente)
- Timo Rheinberger
(University of Twente)
- Vera Flocke
(Heinrich Heine University)
- Anton Windfelder
(Fraunhofer Institute for Molecular Biology and Applied Ecology IME
Justus Liebig University)
- Pascal Bouvain
(Heinrich Heine University)
- Naomi M. Hamelmann
(University of Twente)
- Jos M. J. Paulusse
(University of Twente)
- Hubert Gojzewski
(University of Twente)
- Ulrich Flögel
(Heinrich Heine University)
- Frederik R. Wurm
(University of Twente)
Abstract
In vivo monitoring of polymers is crucial for drug delivery and tissue regeneration. Magnetic resonance imaging (MRI) is a whole-body imaging technique, and heteronuclear MRI allows quantitative imaging. However, MRI agents can result in environmental pollution and organ accumulation. To address this, we introduce biocompatible and biodegradable polyphosphoesters, as MRI-traceable polymers using the 31P centers in the polymer backbone. We overcome challenges in 31P MRI, including background interference and low sensitivity, by modifying the molecular environment of 31P, assembling polymers into colloids, and tailoring the polymers’ microstructure to adjust MRI-relaxation times. Specifically, gradient-type polyphosphonate-copolymers demonstrate improved MRI-relaxation times compared to homo- and block copolymers, making them suitable for imaging. We validate background-free imaging and biodegradation in vivo using Manduca sexta. Furthermore, encapsulating the potent drug PROTAC allows using these amphiphilic copolymers to simultaneously deliver drugs, enabling theranostics. This first report paves the way for polyphosphoesters as background-free MRI-traceable polymers for theranostic applications.
Suggested Citation
Olga Koshkina & Timo Rheinberger & Vera Flocke & Anton Windfelder & Pascal Bouvain & Naomi M. Hamelmann & Jos M. J. Paulusse & Hubert Gojzewski & Ulrich Flögel & Frederik R. Wurm, 2023.
"Biodegradable polyphosphoester micelles act as both background-free 31P magnetic resonance imaging agents and drug nanocarriers,"
Nature Communications, Nature, vol. 14(1), pages 1-8, December.
Handle:
RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-40089-0
DOI: 10.1038/s41467-023-40089-0
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-40089-0. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.